References
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436 - 44; http://dx.doi.org/10.1038/nature07205; PMID: 18650914
- Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success?. J Clin Invest 2008; 118:1991 - 2001; http://dx.doi.org/10.1172/JCI35180; PMID: 18523649
- Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798 - 809; http://dx.doi.org/10.1038/nrc2734; PMID: 19851315
- He G, Karin MNF. -κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011; 21:159 - 68; http://dx.doi.org/10.1038/cr.2010.183; PMID: 21187858
- Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 2011; 54:252 - 61; http://dx.doi.org/10.1002/hep.24339; PMID: 21465510
- Toyonaga T, Hino O, Sugai S, Wakasugi S, Abe K, Shichiri M, et al. Chronic active hepatitis in transgenic mice expressing interferon-γ in the liver. Proc Natl Acad Sci USA 1994; 91:614 - 8; http://dx.doi.org/10.1073/pnas.91.2.614; PMID: 8290572
- Lüth S, Schrader J, Zander S, Carambia A, Buchkremer J, Huber S, et al. Chronic inflammatory IFN-γ signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosis. Cancer Res 2011; 71:3763 - 71; http://dx.doi.org/10.1158/0008-5472.CAN-10-3232; PMID: 21512142
- Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007; 13:1523 - 31; http://dx.doi.org/10.1158/1078-0432.CCR-06-1387; PMID: 17332298